Public Citizen, a prominent consumer
watchdog group, has indicate that the risk of actos bladder cancer from Actos is
further proof that the diabetes drug needs to be removed from the market, and
reinforces their earlier decision to place the drug on their “Do Not Use” list.
This warning has come too late for some, as in the case of Robert Hodges, who
died as a result of complications due to bladder cancer. Judith Hodges, filed a
actos
lawsuit on behalf of her late husband, alleging that his years of Actos use
caused him to suffer severe, permanent and life-threatening personal injuries,
pain, suffering, emotional distress, and a premature death.
Actos (pioglitazone) is a member of a
family of drugs called thiazolidinediones, or glitazones, which have been
linked to a number of health problems of actos
side effects and have not been shown to reduce the
risk of a heart attack or heart failure for diabetics,
which are the main goals of treatment. The family of medications also includes Avandia, which was severely restricted last year due to an increased risk of heart attacks, and Rezulin, which was removed from the market in 2000 due to liver toxicity.The Actos problems with bladder cancer first surfaced in September 2010, when FDA officials released an early communication about interim data from an on-going 10 year study that found Actos users may face an increased risk the longer they take the drug.
Takeda’s problems with Actos do not appear to have an end in sight. In recent months, a growing number of individuals throughout the United States have filed an Actos lawsuit against the drug maker, alleging that it failed to provide adequately warnings for consumers or the medical community about the risk of bladder cancer. Many of the complaints indicate that Takeda should have recalled Actos from the market, arguing that the risk of bladder cancer outweighs the minimal benefits.Hundreds of cases filed by individuals diagnosed with bladder cancer after using the diabetes drug may ultimately be included as part of the Actos litigation in the United States. A panel of judges is scheduled to meet on December 1 to decide whether all federal Actos lawsuits should be consolidated as part of an MDL, or multidistrict litigation.
which are the main goals of treatment. The family of medications also includes Avandia, which was severely restricted last year due to an increased risk of heart attacks, and Rezulin, which was removed from the market in 2000 due to liver toxicity.The Actos problems with bladder cancer first surfaced in September 2010, when FDA officials released an early communication about interim data from an on-going 10 year study that found Actos users may face an increased risk the longer they take the drug.
Takeda’s problems with Actos do not appear to have an end in sight. In recent months, a growing number of individuals throughout the United States have filed an Actos lawsuit against the drug maker, alleging that it failed to provide adequately warnings for consumers or the medical community about the risk of bladder cancer. Many of the complaints indicate that Takeda should have recalled Actos from the market, arguing that the risk of bladder cancer outweighs the minimal benefits.Hundreds of cases filed by individuals diagnosed with bladder cancer after using the diabetes drug may ultimately be included as part of the Actos litigation in the United States. A panel of judges is scheduled to meet on December 1 to decide whether all federal Actos lawsuits should be consolidated as part of an MDL, or multidistrict litigation.
No comments:
Post a Comment